0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

More on Ethics of Drug Discontinuation Studies in Schizophrenia

Thomas C. Neylan, MD; Bruce A. Wright, MD; M. D. Shelton, MD, PhD; Daniel P. van Kammen, MD, PhD
Arch Gen Psychiatry. 1990;47(2):192. doi:10.1001/archpsyc.1990.01810140092016.
Text Size: A A A
Published online

To the Editor.—  Chandler1 raises an objection to the research method of Lieberman et al,2 in which stable schizophrenics were withdrawn from antipsychotic medications and monitored for signs of relapse. He suggests that drug discontinuation studies are unethical. Lieberman et al countered, correctly, that neuroleptics have unacceptable side effects, are ineffective in approximately 30% of patients, and that some patients can remain drugfree for many years without relapse.3As a group that is involved in similar relapse prediction studies, we are very sensitive to the objection raised by Dr Chandler. It is our experience that this discomfort, articulated in the name of ethics, is unfortunately shared by many health care professionals treating schizophrenic patients. Although we agree with Lieberman et al, we feel that an additional response is indicated.We believe that this so-called ethical objection is misguided. It reflects an underlying paternalism, which ignores the fact

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();